Concord Drugs
add_icon

Concord Drugs

75.00
+1.98
(2.71%)
Market Cap
74.98 Cr
PE Ratio
128.11
Volume
433.00
Day High - Low
75.00 - 73.51
52W High-Low
92.52 - 29.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
74.98 Cr
EPS
0.34
PE Ratio
128.11
PB Ratio
2.12
Book Value
34.42
EBITDA
4.10
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
0.99
Debt to Equity
0.54
Forecast For
Actual

Company News

View All News
Caret
positive
Concord Drugs Limited reported strong Q3FY26 results with revenue rising 56.5% to ₹1,686.13 lakhs. Net profit increased to ₹21.52 lakhs from ₹22.19 lakhs in Q3FY25, while nine-month revenue reached ₹4,032.00 lakhs.
neutral
Concord Drugs Limited reconstituted its Board committees on February 14, 2026, and announced the cessation of Director Ramchandra Reddy Kommula due to completion of term.
positive
Concord Drugs Limited announces receipt of significant purchase orders totaling ₹14.71 crores from various government entities including TNMSC and DGHS for pharmaceutical products delivery within 45-60 days.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,799.40
#1 4,31,736.33
39.06
#1 54,729.00
9.71
#1 10,980
16.07
66.49
6,329.00
1,68,015.06
68.15
9,712.00
18.67
2,191
-1.02
52.54
4,317.80
1,46,133.97
64.85
11,539.40
6.99
1,911
26.24
60.63
1,303.80
1,08,819.11
19.84
33,741.20
16.73
5,725
-15.28
58.49
2,343.80
1,07,064.50
22.83
22,909.50
13.74
3,306
#1 37.44
71.29
1,321.20
1,06,722.81
23.63
28,409.50
7.12
5,291
-57.18
41.65
913.05
91,874.19
#1 18.31
23,511.00
18.55
4,615
-0.32
51.93
2,187.00
90,280.47
50.95
12,744.20
#1 20.90
2,007
7.65
54.90
1,231.90
71,548.95
20.43
32,345.60
9.43
3,484
7.59
59.24
5,530.00
66,119.45
27.37
13,458.30
3.70
2,216
1.90
46.88
Growth Rate
Revenue Growth
0.89 %
Net Income Growth
-40.00 %
Cash Flow Change
370.89 %
ROE
-29.29 %
ROCE
5.76 %
EBITDA Margin (Avg.)
1.66 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
16
13
14
14
12
9
8
13
16
12
12
11
10
14
10
17
Expenses
15
12
13
12
11
8
6
12
15
11
12
9
9
13
9
16
EBITDA
1
1
1
1
1
2
2
1
0
1
1
1
1
1
1
1
Operating Profit %
4 %
8 %
9 %
11 %
8 %
16 %
21 %
5 %
2 %
7 %
7 %
13 %
10 %
7 %
11 %
5 %
Depreciation
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
1
0
0
1
1
0
1
1
1
1
1
0
Profit Before Tax
0
0
0
1
0
1
1
-0
-1
0
0
1
0
0
0
0
Tax
0
0
0
0
0
0
0
0
-0
0
0
0
0
0
0
0
Net Profit
0
0
0
0
0
1
1
-0
-0
0
0
0
0
0
0
0
EPS in ₹
0.03
0.21
0.21
0.52
0.17
0.53
0.60
-0.24
-0.34
0.03
0.04
0.23
0.04
0.12
0.19
0.16

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
56
58
59
65
Fixed Assets
14
13
12
12
Current Assets
42
44
38
41
Capital Work in Progress
1
1
2
2
Investments
0
1
1
1
Other Assets
42
44
45
50
Total Equity & Liabilities
56
58
59
65
Current Liabilities
24
22
21
26
Non Current Liabilities
4
5
4
5
Total Equity
28
32
34
34
Reserve & Surplus
20
22
24
24
Share Capital
9
9
10
10

Cash Flow

Cash Flow
2022
2023
2024
2025
Net Cash Flow
0
0
0
0
Investing Activities
-2
-2
-1
-2
Operating Activities
1
2
1
4
Financing Activities
2
1
0
-1

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Oct 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
44.38 %
49.00 %
49.00 %
49.00 %
49.00 %
49.00 %
49.00 %
49.00 %
52.13 %
52.13 %
52.13 %
55.41 %
55.41 %
55.41 %
55.41 %
54.39 %
54.39 %
54.39 %
54.39 %
54.39 %
54.39 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
54.90 %
50.05 %
50.05 %
50.47 %
50.65 %
50.68 %
50.67 %
50.71 %
47.60 %
47.59 %
47.54 %
44.29 %
44.27 %
44.28 %
44.30 %
45.11 %
45.11 %
43.33 %
42.57 %
44.95 %
44.96 %
Others
0.73 %
0.95 %
0.95 %
0.53 %
0.35 %
0.32 %
0.33 %
0.29 %
0.27 %
0.28 %
0.33 %
0.30 %
0.32 %
0.31 %
0.29 %
0.50 %
0.50 %
2.28 %
3.04 %
0.66 %
0.65 %
No of Share Holders
2,173
2,826
2,826
3,071
3,047
3,036
3,188
3,321
3,215
3,198
3,957
3,963
4,032
4,734
4,755
5,073
5,073
5,252
5,189
4,718
4,597

Announcements

Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 17, 2026
General UpdateFeb 16, 2026
Financial Results For Quarter Ended 31St Dec2025Feb 14, 2026
Board Meeting Outcome for Out Come Of Board MeetingsFeb 14, 2026
Reconstitution Of CommitteesFeb 14, 2026
Announcement under Regulation 30 (LODR)-RetirementFeb 14, 2026
Board Meeting Intimation for Quarterly ResultsFeb 02, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 20, 2026
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderDec 30, 2025
Closure of Trading WindowDec 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 25, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 25, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 25, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Nov 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 22, 2025
Board Meeting Outcome for Outcome Of Board Meeting For Allotment Of Equity Shares And Convertible WarrantsNov 20, 2025
Announcement under Regulation 30 (LODR)-AllotmentNov 20, 2025
Financial Results For Quarter Ended 30 Sep 2025Nov 13, 2025
Board Meeting Outcome for Outcome Of Board MeetingNov 13, 2025
Board Meeting Intimation for Quarterly ResultsNov 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 11, 2025
Reg. 34 (1) Annual Report.Sep 09, 2025
Letter To ShareholdersSep 08, 2025
Annual ReportSep 08, 2025
Notice For AGMSep 08, 2025
Record Date For AGMSep 08, 2025
Book Closure For AGMSep 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 08, 2025
Board Meeting Outcome for Out Come Of Board MeetingSep 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 11, 2025
Financial Results For Quarter Ending 30 June 2025Aug 08, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 08, 2025
Board Meeting Intimation for Quarterly ResultsAug 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAug 01, 2025
Shareholder Meeting / Postal Ballot-Outcome of EGMJul 31, 2025
Corrigendum To The Notice Of EGMJul 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Notice Of EGMJul 09, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationJul 03, 2025
Board Meeting Outcome for Out Come Of Board MeetingJul 03, 2025
Clarification Letter Sought From BSEJul 02, 2025
Clarification sought from Concord Drugs LtdJul 02, 2025
Board Meeting Intimation for Issue Of Shares Through Preferential AllotmentJun 30, 2025
Board Meeting Outcome for Outcome Of Board MeetingJun 27, 2025
Closure of Trading WindowJun 26, 2025
Board Meeting Intimation for Considering And Approval Of Preferential IssueJun 19, 2025

Technical Indicators

RSI(14)
Neutral
39.05
ATR(14)
Less Volatile
4.78
STOCH(9,6)
Oversold
15.85
STOCH RSI(14)
Oversold
6.28
MACD(12,26)
Bearish
-1.10
ADX(14)
Weak Trend
17.00
UO(9)
Bearish
33.05
ROC(12)
Downtrend And Accelerating
-14.53
WillR(14)
Oversold
-89.70